What were the key takeaways from Rockwell Medical's earnings call?

Did Rockwell Medical beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Rockwell Medical year over year?

What were the key takeaways from Rockwell Medical’s earnings call?

What guidance did Rockwell Medical's management provide for the next earnings period?

What is the market's earnings forecast for Rockwell Medical next quarter?

What is Rockwell Medical's gross profit margin?

What is Rockwell Medical's latest dividend and current dividend yield?

- **Profitability milestone**: Q3 2025 adjusted EBITDA turned positive ($50K vs. -$200K Q2). 
- **Customer diversification**: Reduced reliance on largest customer to 12% of sales (from prior dominance). 
- **Cash strength**: $23.7M cash (34% QoQ increase) fuels 2026 M&A and growth initiatives. 
- **High-margin growth**: Bicarbonate cartridge adoption could add $1M+ annually, home dialysis market poised for 10-15% penetration. 
- **Operational efficiency**: 2025 restructuring saves $1.2M+ through plant closures and labor optimization.

**【CEO Summary Section】**
- Rockwell Medical achieved profitability on an adjusted EBITDA basis in Q3 2025, with $50,000 compared to negative $200,000 in Q2. 
- Despite a 44% YoY decline in net sales to $15.9 million due to the largest customer transition, gross margin stabilized at 14% (18% excluding restructuring costs). 
- Secured new contracts including a 3-year $1M+ annualized deal in Florida and expanded agreement with the largest dialysis provider, reducing reliance on any single customer to 12% of Q3 sales. 
- Bicarbonate cartridge launch is driving high-margin growth, with major customer adoption expected to accelerate in 2026. 
- West Coast expansion and home dialysis market (currently single-digit penetration) are key growth areas.

**【CFO Financial Commentary】**
- Cash position strengthened to $23.7 million (up 34% QoQ) from stock issuance and asset acquisition. 
- 2026 guidance expected in Q1 2026, with focus on labor cost efficiency and facility closures (e.g., $1.2M savings from plant consolidation). 
- Gross margin improved sequentially to 18% (non-restructured basis), with EBITDA trending positive despite 34% YoY revenue decline. 
- Acquisitions and customer base expansions are priorities for 2026 growth.

**【Q&A Key Highlights】**
- Largest customer transition expected to resolve in Q4 2025, with Rockwell maintaining 12% sales contribution despite supplier recall challenges. 
- 2026 guidance will include acquisitions and customer base expansions, targeting labor and distribution cost reductions. 
- Home dialysis market potential at 10-15% of total, with Rockwell's new product configurations driving higher-margin opportunities. 
- West Coast expansion plans include facility consideration for critical mass of new customers.

Rockwell Medical, Inc. (RMTI) Q3 2025 Earnings Call Transcript

- **Revenue Impact**: Q2 sales down 38% YoY due to largest customer loss, but stable 16% gross margin reflects cost management.
- **Diversification Success**: 80% of revenue now from long-term contracts, reducing concentration risk to <10% from largest customer.
- **Growth Opportunities**: $100M Western US expansion and potential Q4 upside from DaVita deal.
- **Financial Resilience**: Positive cash flow ($1.8M) and stable margins despite revenue decline, positioning for 2026 predictability.
- **Strategic Focus**: Automation investments and customer acquisition driving future efficiency and growth.

**【CEO Opening Remarks】**
- **Transition Year Progress**: Despite losing a major customer, Rockwell maintained stability with Q2 cash flow positive from operations and gross margin consistent at 16%.
- **New Contracts**: Secured multimillion-dollar agreements with IRC (3-year), a rural health system (2-year), and South Florida providers, reducing reliance on a single customer.
- **Customer Concentration Mitigation**: 80% of customers now on long-term contracts, down from 40-45% previously, with largest customer now contributing <10% of revenue.
- **2025 Guidance**: Reiterated net sales $65-70M, gross margin 16-18%, and adjusted EBITDA -$500k to +$500k.

**【CFO Financial Commentary】**
- **Revenue Decline**: Q2 net sales $16.1M (-38% YoY) due to largest customer transition, with H1 2025 sales $35M (-28% YoY).
- **Gross Profit**: Q2 gross profit $2.5M (-45% YoY), H1 $5.5M (-27% YoY), with stable 16% gross margin.
- **EBITDA**: Q2 adjusted EBITDA -$200k (improvement from Q1 -$400k), H1 -$700k vs. +$900k YoY.
- **Cash Position**: $18.4M at end of Q2 (+$1.8M from operations).

**【Q&A Highlights】**
- **Western US Expansion**: Targeting $100M opportunity with DaVita and Fresenius; expects clarity post Q3 negotiations.
- **DaVita Negotiations**: Optimistic for long-term supply agreement; potential Q4 financial impact if finalized.
- **Capital Allocation**: Prioritizing automation investments (e.g., manufacturing efficiency) and new customer acquisition over debt repayment.
- **Gross Margin Stability**: Achieved via staff reductions, equipment upgrades, and minimal margin contribution from largest customer.
- **Competitor Recall Impact**: Supplemented competitor's supply during recall, reinforcing Rockwell's reliability in critical patient care.


Rockwell Medical, Inc. (RMTI) Q2 2025 Earnings Call Transcript

- **Revenue decline driven by customer loss**: Q1 2025 net sales down 17% to $18.9M due to largest customer transition. 
- **Gross margin improvement**: 16% in Q1 2025 (vs. 14% YoY) from cost optimization. 
- **New product opportunity**: Bicarbonate cartridge launch in Feb 2025 targeting high-growth dialysis segment. 
- **Q2 expected to be trough**: CFO projects Q2 as weakest quarter with recovery in H2. 
- **Latin America growth engine**: International expansion focused on emerging dialysis centers. 


**【CEO Summary Section】**
- **Q1 2025 Performance**: Revenue of $18.9M (-17% YoY) due to largest customer transitioning to a competitor. Gross margin improved to 16% (vs. 14% in Q1 2024). 
- **Customer Diversification**: Signed new contracts with regional/national dialysis providers; 90% of revenue remains U.S.-based. 
- **New Product Launch**: Bicarbonate cartridge launched in Feb 2025, targeting fastest-growing dialysis segment. 
- **2025 Guidance**: Net sales $65-70M, gross margin 16-18%, adjusted EBITDA (-$0.5M to +$0.5M). 
- **Cybersecurity Update**: No impact from recent industry ransomware attack; systems disconnected proactively. 
- **Tariff Impact**: Minimal (1% of revenue) as 90% of products manufactured in U.S. 

**【CFO Financial Commentary】**
- **Net Loss**: $1.5M (vs. $1.7M YoY), driven by $900K one-time payment from largest customer. 
- **Cash Position**: $17.3M (down from $21.6M at year-end due to seasonal expenses). 
- **Adjusted EBITDA**: -$0.4M (sequential improvement from -$0.5M in Q4 2024). 

**【Q&A Key Highlights】**
- **Largest Customer Negotiations**: Discussions for scaled-down agreement to replenish safety stock; no timeline for resolution. 
- **Revenue Cadence**: Q2 likely weakest quarter; Q3+ growth driven by new customer wins. 
- **At-Home Dialysis**: High-margin product seeing early traction; expects meaningful contribution in H2 2025. 
- **West Coast Expansion**: Exploring facility in West to serve underpenetrated market; no decision yet. 
- **Latin America Growth**: Emerging dialysis centers driving international expansion. 


Rockwell Medical (RMTI)-12 May 25-2025 Q1 Earnings call transcript

- **2024 Milestone Achievement**: $101.5M net sales, 17% gross margin, and first full-year adjusted EBITDA profitability.
- **2025 Transition Plan**: $65-70M net sales guidance due to $34M loss from largest customer transition; targeting 16-18% gross margin.
- **Growth Drivers**: New products (bicarbonate cartridges, convenience packs), international expansion (30+ countries), and cost reductions ($2+M annually).
- **Financial Strength**: $21.6M cash balance, reduced net loss, and strong balance sheet for 2025 execution.

**【CEO Summary Section】**
- Achieved full-year 2024 net sales of $101.5 million, gross margin of 17%, and first-time full-year adjusted EBITDA profitability.
- Largest customer will transition away by June 30, 2025, resulting in $34 million revenue loss compared to 2024.
- 2025 guidance: $65-70 million net sales, 16-18% gross margin, and adjusted EBITDA near breakeven.
- Focus on diversifying customer base, product portfolio, and cost optimization.

**【CFO Financial Commentary】**
- Q4 2024 net sales: $24.7 million (12% YoY growth); full-year 2024: $101.5 million (21% YoY growth).
- Gross profit improved to $17.5 million (vs. $8.7 million in 2023), driven by price increases and cost reductions.
- Net loss reduced to $500,000 (vs. $8.4 million in 2023); adjusted EBITDA: $5.2 million (vs. -$3.9 million in 2023).
- Cash balance: $21.6 million at year-end, up from $10.9 million in 2023.

**【Commercial Strategy Highlights】**
- Expanded into new markets with convenience packs, single-use bicarbonate cartridges, and international agreements (e.g., Nephro Group in Philippines).
- Signed $10 million+ product purchase agreement with leading dialysis provider and distribution deal with Nipro Medical for global expansion.
- Targeting 14.5 million gallons of potential US business and $100 million opportunity in single-use bicarbonate cartridges.

**【Q&A Highlights】**
- Largest customer transition: discussions ongoing for potential future agreements, but no impact on 2025 guidance.
- 2025 strategy: replace lost revenue with new customers, reduce expenses by $2+ million annually, and focus on high-margin international sales.
- Bicarbonate cartridge growth: targeting existing customers first, with long-term potential in machine-compatible cartridge adoption.
- West Coast expansion: exploring dedicated facilities as sales grow, leveraging current distribution network.


Rockwell Medical (RMTI)-20 Mar 25-2024 Q4 Earnings call transcript

Rockwell Medical (RMTI)-12 Nov 24-2024 Q3 Earnings call transcript

Rockwell Medical (RMTI)-8 Aug 24-2024 Q2 Earnings call transcript

Rockwell Medical (RMTI)-14 May 24-2024 Q1 Earnings call transcript

Rockwell Medical (RMTI)-21 Mar 24-2023 Q4 Earnings call transcript

Rockwell Medical (RMTI)-14 Nov 23-2023 Q3 Earnings call transcript

Rockwell Medical (RMTI)-15 May 23-2023 Q1 Earnings call transcript

Rockwell Medical (RMTI)-30 Mar 23-2022 Q4 Earnings call transcript

Rockwell Medical (RMTI)-14 Nov 22-2022 Q3 Earnings call transcript

Rockwell Medical (RMTI)-15 Aug 22-2022 Q2 Earnings call transcript

Rockwell Medical (RMTI)-17 May 22-2022 Q1 Earnings call transcript

Rockwell Medical (RMTI)-16 Nov 21-2021 Q3 Earnings call transcript

Rockwell Medical (RMTI)-17 Aug 21-2021 Q2 Earnings call transcript

Rockwell Medical (RMTI)-17 May 21-2021 Q1 Earnings call transcript

Rockwell Medical (RMTI)-1 Apr 21-2020 Q4 Earnings call transcript

Rockwell Medical (RMTI)-9 Nov 20-2020 Q2 Earnings call transcript

Rockwell Medical (RMTI)-11 May 20-2020 Q1 Earnings call transcript

Rockwell Medical (RMTI)-12 Mar 20-2019 Q4 Earnings call transcript

Rockwell Medical (RMTI)-11 Nov 19-2019 Q3 Earnings call transcript

Rockwell Medical (RMTI)-8 Aug 19-2019 Q2 Earnings call transcript

Rockwell Medical (RMTI)-9 May 19-2019 Q1 Earnings call transcript

Rockwell Medical (RMTI)-14 Mar 19-2018 Q4 Earnings call transcript

Rockwell Medical (RMTI)-9 Nov 18-2018 Q3 Earnings call transcript

Rockwell Medical (RMTI)-15 Aug 18-2018 Q2 Earnings call transcript

Rockwell Medical (RMTI)-10 May 18-2018 Q1 Earnings call transcript

Rockwell Medical (RMTI)-15 Mar 18-2017 Q4 Earnings call transcript

Rockwell Medical (RMTI)-8 Nov 17-2017 Q3 Earnings call transcript

RMTI

RMTI fundamentals

Earnings Call

You can ask Aime